Organisation paid for research Program year 2025 Source: CMS Open Payments

Kerwin Research Center LLC

Neither a doctor nor a teaching hospital

Research payments

$2,271,934

236 payments

Through program year 2025, Kerwin Research Center LLC is reported as receiving $2,271,934 in research payments, across 236 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$33,908	9
2024	Research	$218,066	9
2023	Research	$459,962	16
2022	Research	$90,071	8
2021	Research	$519,491	33
2020	Research	$696,258	100
2019	Research	$254,178	61

Breakdown

Who paid Research payments · program years 2019–2025

Eisai Inc. $1,372,637 113 payments
AbbVie, Inc. $523,941 48 payments
Genentech, Inc. $303,909 48 payments
Eli Lilly and Company $46,485 20 payments
Biohaven Pharmaceuticals, Inc. $19,324 6 payments
Biohaven Pharmaceutical Holding Company Ltd. $5,639 1 payment

Studies the money was for Research payments · program years 2019–2025

A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $1,279,002 44 payments
Gantenerumab in Early Ad $229,616 37 payments
M15-570 $172,305 13 payments
M15-566 $160,416 13 payments
An Extension Study of ABBV-8E12 in Early Alzheimers Disease $136,550 8 payments
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies $77,490 64 payments
Prodromal to Mild Ad $74,293 11 payments
M15-562 $28,030 2 payments
A 24-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of Azd3293 in Early Alzheimers Disease -The Amaranth Study $20,936 1 payment
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) $19,324 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.